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A non-invasive urine based biomarker that is highly 
sensitive and specific is the ideal test to reduce the need 
for cystoscopy to detect bladder cancer. This is an area of 
much research with proof of concept reports showing a 
varying level of diagnostic accuracy using protein, genomic, 
transcriptomic and epigenetic based markers. 
In this issue of the British Journal of Urology International, 
Pichler and colleagues reported the diagnostic accuracy 
of Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA) as 
a cross sectional prospective observational study of 140 
patients having cystoscopy as part of non-muscle invasive 
bladder cancer (NMIBC) surveillance (1). The Xpert 
BC Monitor represents a point of care polymerase chain 
reaction (PCR) based test interrogating 5 target mRNAs 
(ABL1, CRH, IGF2, UPK1B, ANXA10). In this study, the 
result of the Xpert BC Monitor was compared to urinary 
cytology which was evaluated using the Paris classification 
system, with cystoscopy representing the reference test. 
Pichler and colleagues report that Xpert BC Monitor had a 
superior overall sensitivity (84%), negative predictive value 
(NPV) (93%) and area under curve (0.87) compared to 
urinary cytology washings. In addition, sensitivity for low 
grade tumours was 77% although there was no difference in 
specificity (91%). 
The Xpert BC Monitor platform is attractive for several 
reasons. It is a point of care test, requiring only 4 ml of 
urine and requires minimal hands on preparation time 
as it is automated. The single use disposable cartridges 
minimise cross contamination between different urine 
samples and are easy to use. With regards to its diagnostic 
accuracy, it successfully identified all but one high risk 
NMIBC (one pT1 tumour was missed) suggesting a 
high sensitivity. Identifying all high-risk bladder cancer 
is of paramount importance to allow early treatment and 
prevent disease progression. However, 7 of 31 low grade 
tumours were missed by the Xpert BC Monitor although a 
delay in diagnosis of these patients would pose a minimal 
risk (2). These results suggest a marginally better diagnostic 
accuracy compared to the six Food and Drug Administration 
(FDA) commercially approved urinary biomarkers with an 
overall sensitivity of 57–82% and specificity of 74–88% (3).  
However,  are such results sufficient to replace 
cystoscopy? The reason for the lack of uptake in urinary 
biomarker use is because none of the FDA approved tests 
are licensed for use as stand-alone tests without cystoscopy. 
The heterogeneous nature of bladder cancer suggests that 
a 5 panel biomarker may not be sufficient to identify all 
tumours (4). Other groups have reported biomarker panels 
ranging from 8 to 150 targets with a higher diagnostic 
accuracy (5,6). In addition, comparing the diagnostic 
ability of urinary cytology to Xpert BC Monitor serves 
little purpose. Urinary cytology only has value in high 
grade NMIBC as an adjunct to cystoscopy and not as a 
stand-alone test. The fact that nearly all high risk NMIBC 
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were identified suggest a role in the surveillance setting to 
increase the interval between surveillance cystoscopies as 
previously suggested (7,8). 
Recommendations for NMIBC surveillance vary between 
guidelines and incorporating urinary biomarkers will require 
future studies to determine the best oncologically sound and 
cost-effective approach (9). While Pichler and colleagues 
should be congratulated for their study, many groups have 
reported different biomarker panels with impressive results. 
Hence, well-designed blinded prospective observational 
studies are required to validate such biomarkers before wide 
spread adoption (10). 
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